Coherus Oncology Inc’s recently made public that its Director Wahlstrom Mats unloaded Company’s shares for reported $73881.0 on May 23 ’25. In the deal valued at $0.74 per share,99,988 shares were sold. As a result of this transaction, Wahlstrom Mats now holds 0 shares worth roughly $0.0.
UBS downgraded its Coherus Oncology Inc [CHRS] rating to a Neutral from a a Buy in a research note published on August 16, 2024; the price target was decreased to $1.50 from $4. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. Maxim Group also remained covering CHRS and has decreased its forecast on November 08, 2023 with a “Hold” recommendation from previously “Buy” rating. Citigroup started covering the stock on July 24, 2023. It rated CHRS as “a Buy”.
Price Performance Review of CHRS
On Monday, Coherus Oncology Inc [NASDAQ:CHRS] saw its stock fall -1.12% to $0.87. Over the last five days, the stock has lost -18.88%. Coherus Oncology Inc shares have fallen nearly -43.64% since the year began. Nevertheless, the stocks have fallen -37.10% over the past one year.
How much short interest is there in Coherus Oncology Inc?
A steep rise in short interest was recorded in Coherus Oncology Inc stocks on 2025-07-15, dropping by -0.71 million shares to a total of 31.23 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 31.94 million shares. There was a decline of -2.29%, which implies that there is a negative sentiment for the stock.